Foghorn Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $2,856 | $7,808 | $6,888 | $5,050 |
Gross Profit | 2,856 | 7,108 | 6,088 | 4,215 |
EBITDA | -23,244 | -23,852 | -23,443 | -27,359 |
EBIT | -24,005 | -24,585 | -24,243 | -28,194 |
Net Income | -19,503 | -19,122 | -22,979 | -25,016 |
Net Change In Cash | 2,856 | 7,808 | 6,888 | 5,050 |
Free Cash Flow | -24,998 | -21,314 | -25,554 | -29,446 |
Cash | 55,454 | 57,678 | 138,947 | 79,253 |
Basic Shares | 62,602 | 62,602 | 51,580 | 42,428 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $22,602 | $34,155 | $19,228 | $1,319 |
Gross Profit | 22,602 | -75,534 | 19,208 | -6,196 |
EBITDA | -97,165 | -104,455 | -113,816 | -96,187 |
EBIT | -100,285 | -107,906 | -117,137 | -103,702 |
Net Income | -86,620 | -98,426 | -108,873 | -103,226 |
Net Change In Cash | 22,602 | 34,155 | 19,228 | 1,319 |
Cost of Revenue | -48,947 | 8,341 | ||
Free Cash Flow | -101,312 | -119,330 | 192,402 | -53,563 |
Cash | 55,454 | 80,336 | 345,798 | 101,136 |
Basic Shares | 54,899 | 41,974 | 41,591 | 37,171 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.30 |
2024-09-30 | -$0.31 |
2024-06-30 | -$0.45 |
2024-03-31 | -$0.59 |
